Patrick c. Reading - Infectious Diseases

Author Information

Patrick C. Reading is a distinguished researcher affiliated with the WHO Collaborating Centre for Reference and Research on Influenza, situated within the Victorian Infectious Diseases Reference Laboratory at the Peter Doherty Institute for Infection and Immunity in Melbourne, Victoria, Australia. His work primarily focuses on infectious diseases, with a particular emphasis on influenza and respiratory viruses. Through his research, Patrick C. Reading contributes significantly to the scientific community's understanding and development of vaccines and antiviral strategies against these pathogens.

Research Contributions

Patrick C. Reading has made substantial contributions to the field of infectious diseases, particularly in the study of influenza and respiratory viruses. His research encompasses the development of vaccines, understanding viral mechanisms, and enhancing laboratory practices for virus identification. Notable works include the development of molecular clamp stabilized vaccines for Influenza A viruses, studies on the immune response against SARS-CoV-2, and investigations into the innate immune responses in the respiratory tract that provide protection against viral infections.

Aliases

Patrick C. Reading is also known by various aliases in the academic community, including Patrick Reading, Patrick\u2004c. Reading, and Patrick C Reading. These variations are often used interchangeably in scientific publications and databases.

Publication and Citation Metrics

Metric	Value
Total Papers	149
Total Citations	8966
H-index	51

Publications:

Author Correction: Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses

DOI: 10.1038/s41541-021-00428-y

Year: 2022

COVID-19 in Fiji

DOI: 10.1071/ma21053

Year: 2021

TLR2-mediated activation of innate responses in the upper airways confers antiviral protection of the lungs

DOI: 10.1172/jci.insight.140267

Year: 2021

Predicting potentially permissive substitutions that improve the fitness of A(H1N1)pdm09 viruses bearing the H275Y NA substitution

DOI: 10.1101/2021.03.21.436293

Year: 2021

MARCH8 Restricts Influenza A Virus Infectivity but Does Not Downregulate Viral Glycoprotein Expression at the Surface of Infected Cells

DOI: 10.1128/mBio.01484-21

Year: 2021

A second external quality assessment of isolation and identification of influenza viruses in cell culture in the Asia Pacific region highlights improved performance by participating laboratories.

DOI: 10.1016/j.jcv.2021.104907

Year: 2021

Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial

DOI: 10.1016/S1473-3099(21)00200-0

Year: 2021

Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2

DOI: 10.1002/cti2.1269

Year: 2021

Development of molecular clamp stabilized hemagglutinin vaccines for Influenza A viruses

DOI: 10.1038/s41541-021-00395-4

Year: 2021

IFITM Proteins That Restrict the Early Stages of Respiratory Virus Infection Do Not Influence Late-Stage Replication

DOI: 10.1128/JVI.00837-21

Year: 2021

What Is the Future of Malaria Research?

What is the Global Fund?

How Important is Healthcare Worker Safety?

When Should Symptomatic Relief Be Used?

What is Glycolysis?

Can Symptomatic Relief Replace Primary Treatment?

What are the Benefits of Gene Therapy and Immunotherapy?

How Do Contaminants Enter Food and Water?

What are Respiratory Symptoms?

How Do Bacterial Infections Spread?

Partnered Content Networks

Relevant Topics